Evidence map›Paper›PMID 26866805›Full record

ArticlePloS one2016

Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes.

Inês G Mollet, Dilipkumar Patel, Fatima S Govani, Adam Giess, Koralia Paschalaki, Manikandan Periyasamy, Elaine C Lidington, Justin C Mason, Michael D Jones, Laurence Game and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Iron Metabolism in Aging and Age-Related Diseases.International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Journal of Alzheimer's disease reports · 2021
    Article
  16. Review
  17. Article
  18. [Anti-CD206 antibody-conjugated FeNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Inês G MolletNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Dilipkumar PatelNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Fatima S GovaniNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Adam GiessMedical Research Council Clinical Sciences Centre, Imperial College London, London, United Kingdom.
Koralia PaschalakiNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Manikandan PeriyasamyDepartment of Surgery & Cancer, Imperial College London, London, United Kingdom.
Elaine C LidingtonNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Justin C MasonNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Michael D JonesMedical Research Council Clinical Sciences Centre, Imperial College London, London, United Kingdom.
Laurence GameMedical Research Council Clinical Sciences Centre, Imperial College London, London, United Kingdom.
Simak AliDepartment of Surgery & Cancer, Imperial College London, London, United Kingdom.
Claire L ShovlinNHLI Cardiovascular Sciences, Imperial College London, London, United Kingdom.
Imperial College London · GB

Funding

British Heart Foundation PG/09/041/27515Cancer Research UK 18784
6 · The paper itself

Abstract

backgroundSpontaneous reports from patients able to report vascular sequelae in real time, and recognition that serum non transferrin bound iron may reach or exceed 10μmol/L in the blood stream after iron tablets or infusions, led us to hypothesize that conventional iron treatments may provoke acute vascular injury. This prompted us to examine whether a phenotype could be observed in normal human endothelial cells treated with low dose iron. METHODOLOGY: Confluent primary human endothelial cells (EC) were treated with filter-sterilized iron (II) citrate or fresh media for RNA sequencing and validation studies. RNA transcript profiles were evaluated using directional RNA sequencing with no pre-specification of target sequences. Alignments were counted for exons and junctions of the gene strand only, blinded to treatment types. PRINCIPAL

findingsRapid changes in RNA transcript profiles were observed in endothelial cells treated with 10μmol/L iron (II) citrate, compared to media-treated cells. Clustering for Gene Ontology (GO) performed on all differentially expressed genes revealed significant differences in biological process terms between iron and media-treated EC, whereas 10 sets of an equivalent number of randomly selected genes from the respective EC gene datasets showed no significant differences in any GO terms. After 1 hour, differentially expressed genes clustered to vesicle mediated transport, protein catabolism, and cell cycle (Benjamini p = 0.0016, 0.0024 and 0.0032 respectively), and by 6 hours, to cellular response to DNA damage stimulus most significantly through DNA repair genes FANCG, BLM, and H2AFX. Comet assays demonstrated that 10μM iron treatment elicited DNA damage within 1 hour. This was accompanied by a brisk DNA damage response pulse, as ascertained by the development of DNA damage response (DDR) foci, and p53 stabilization. SIGNIFICANCE: These data suggest that low dose iron treatments are sufficient to modify the vascular endothelium, and induce a DNA damage response.

Indexed as

Cell CycleCitratesCluster AnalysisComet AssayDNA DamageDose-Response Relationship, DrugEndothelial CellsExonsGene Expression ProfilingGene Expression RegulationHistonesHumansHuman Umbilical Vein Endothelial CellsIronMicrocirculationPhenotypeCitratesH2AX protein, humanHistonesIronTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26866805
PMCPMC4750942
OpenAlexW2269561980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.